Endpoints News· @endpts · X·· 3 小时前精选AI 评分62
AI 导读
吉利德与Vir达成交易，针对三款面向实体瘤的T细胞衔接器，吉利德将支付6500万美元首付款。交易细节见Endpoints News报道链接。
推荐理由
交易披露了首付款金额与三款实体瘤T细胞衔接器资产，可观察吉利德在实体瘤方向的BD布局。
正文
Gilead is paying Vir $65M upfront in a deal for three T cell engagers aimed at solid tumors. https://endpoints.news/vir-makes-solid-tumor-t-cell-engager-deal-with-gilead/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源：Endpoints News · x.com